BridgeBio's Acoramidis Shows Stronger Real-World Outcomes Than Tafamidis in ATTR-CM Study
Event summary
- Acoramidis demonstrated an 18% lower risk of composite adverse outcomes (death, hospitalization, atrial fibrillation, diuretic intensification) compared to tafamidis in a real-world study of 2,684 ATTR-CM patients.
- The study, using Epic COSMOS data, showed a 27% reduction in cardiovascular and heart failure hospitalizations with acoramidis versus tafamidis.
- Results were consistent across unadjusted, matched, and biomarker-adjusted analyses, with early separation of outcomes within one month.
- Additional HFSA 2026 presentations reinforced the importance of reducing hospitalizations in ATTR-CM and showed differentiated benefits of acoramidis in specific patient subgroups.
The big picture
This study provides strong real-world evidence supporting acoramidis' superiority over tafamidis in reducing critical adverse outcomes in ATTR-CM patients. The findings come at a time when real-world data is increasingly influencing treatment decisions in rare diseases, potentially shifting market dynamics in favor of BridgeBio. The results also highlight the growing importance of hospitalization reduction as a key clinical endpoint in ATTR-CM management.
What we're watching
- Competitive Positioning
- Whether BridgeBio can leverage these real-world results to position acoramidis as the preferred treatment for ATTR-CM, potentially capturing market share from tafamidis.
- Long-Term Efficacy
- The pace at which additional long-term data will confirm whether the observed benefits of acoramidis are sustained over longer follow-up periods.
- Regulatory and Clinical Strategy
- How BridgeBio will use these findings to support potential label expansions or new indications for acoramidis, particularly in specific patient subgroups.